Emerging commercial molecular tests for the diagnosis of bloodstream infection

Mwaigwisya, Solomon, Assiri, Rasha Assad M and O'Grady, Justin (2015) Emerging commercial molecular tests for the diagnosis of bloodstream infection. Expert Review of Molecular Diagnostics, 15 (5). pp. 681-692. ISSN 1744-8352

[img] Microsoft Word (Expert review paper - revision clean 2-3-15) - Draft Version
Download (217kB)

Abstract

Bloodstream infection (BSI) by microorganisms can lead to sepsis. This condition has a high mortality rate, which rises significantly with delays in initiation of appropriate antimicrobial treatment. Current culture methods for diagnosing BSI have long turnaround times and poor clinical sensitivity. While clinicians wait for culture diagnosis, patients are treated empirically, which can result in inappropriate treatment, undesirable side effects and contribute to drug resistance development. Molecular diagnostics assays that target pathogen DNA can identify pathogens and resistance markers within hours. Early diagnosis improves antibiotic stewardship and is associated with favorable clinical outcomes. Nonetheless, limitations of current molecular diagnostic methods are substantial. This article reviews recent commercially available molecular methods that use pathogen DNA to diagnose BSI, either by testing positive blood cultures or directly testing patient blood. We critically assess these tests and their application in clinical microbiology. A view of future directions in BSI diagnosis is also provided.

Item Type: Article
Uncontrolled Keywords: antibiotic resistance,blood culture,blood stream infection,maldi-tof,molecular diagnostics,next-generation sequencing,ngs,pcr,esi-ms,sepsis
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 24 Jul 2015 23:00
Last Modified: 22 Jul 2020 00:18
URI: https://ueaeprints.uea.ac.uk/id/eprint/53783
DOI: 10.1586/14737159.2015.1029459

Actions (login required)

View Item View Item